Trials / Completed
CompletedNCT06232252
A Study to Test How Well Multiple Doses of BI 765423 Are Tolerated by Healthy Men
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Intravenous Doses of BI 765423 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled, Parallel Group Design)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics of BI 765423 in healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 765423 | BI 765423 |
| DRUG | Placebo matching BI 765423 | Placebo matching BI 765423 |
Timeline
- Start date
- 2024-05-06
- Primary completion
- 2025-04-25
- Completion
- 2025-04-29
- First posted
- 2024-01-30
- Last updated
- 2025-06-25
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT06232252. Inclusion in this directory is not an endorsement.